A first step against idiopathic pulmonary fibrosis

Crestani, Bruno

doi:10.1183/09059180.00003711

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, it has been shown that the combination of low-dose steroids, azathioprine and NAC may provide some benefit, mainly in patients with mild-to-moderate disease defined by a composite physiological index ,50 [13,14]. Pirfenidone, a drug with antifibrotic and anti-inflammatory properties has been proven to significantly slow the decline of forced vital capacity and to increase progression-free survival with an acceptable safety profile [116][117][118][119]. Recently, it has been suggested that multiple pathways could be simultaneously involved in the pathogenesis of IPF [120].…”

Section: Resultsmentioning

confidence: 99%

Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis

Margaritopoulos¹,

Romagnoli²,

Poletti³

et al. 2012

Eur Respir Rev

View full text Add to dashboard Cite

Interstitial lung diseases (ILDs) are a group of heterogeneous disorders, either idiopathic or associated with injurious or inflammatory causes, in which the major site of damage is the lung interstitium. For a long time, knowledge regarding pathogenesis was trivial and there were difficulties in diagnosing and subsequently treating these diseases.During the past decade, however, there has been an impressive development in the field of ILDs. Idiopathic pulmonary fibrosis, the most common and fatal form of ILD, was initially believed to be due to an inflammatory response to unknown lung injury, whereas nowadays it is believed to be the result of multiple injuries at different sites of the lung followed by aberrant repair.The integration of clinical, radiological and histological data, namely a multidisciplinary team (MDT) approach, has provided grounds for a more accurate diagnosis of ILDs, and helped the identification of different entities and development of different therapeutic approaches. However, because of the complexity of ILDs, even this approach may fail to establish a confident diagnosis.How should the clinician behave in this case and what are the pitfalls of the MDT approach? In addition, since diagnosis is the major predictor of prognosis, are there any other tools available to predict prognosis?

show abstract

Section: Resultsmentioning

confidence: 99%

Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis

Margaritopoulos¹,

Romagnoli²,

Poletti³

et al. 2012

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

“…EMT also enables cells to acquire invasive properties, thus degrading ECM and synthesizing new ECM components [55] . Several recent studies indicate that ROS production by NOXs plays a central role in the pathogenesis of pulmonary fibrosis and inflammation [47] , [56] , [57] , [58] , [59] . A recent study has found that TGF-β1 regulated the expression of NOX4, one of the major cellular ROS sources, thus generating oxidative stress [59] .…”

Section: Oxidative Stress and Fibrosismentioning

confidence: 99%

Role of redoximiRs in fibrogenesis

2016

View full text Add to dashboard Cite

Fibrosis can be defined as an excessive accumulation of extracellular matrix (ECM) components, ultimately leading to stiffness, scarring and devitalized tissue. MicroRNAs (miRNAs) are short, 19–25 nucleotides (nt), non-coding RNAs involved in the post-transcriptional regulation of gene expression. Recently, miRNAs have also emerged as powerful regulators of fibrotic processes and have been termed “fibromiRs”. Oxidative stress represents a self-perpetuating mechanism in fibrogenesis. MiRNAs can also influence the expression of genes responsible for the generation of reactive oxygen species (ROS) and antioxidant defence and are termed “redoximiRs”. Here, we review the current knowledge of mechanisms by which “redoximiRs” regulate fibrogenesis. This new set of miRNAs may be called “redoxifibromiRs”.

show abstract

A first step against idiopathic pulmonary fibrosis

Cited by 2 publications

References 17 publications

Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis

Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis

Role of redoximiRs in fibrogenesis

Contact Info

Product

Resources

About